Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NEOG's Cash-to-Debt is ranked higher than
97% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. NEOG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NEOG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.89
NEOG's Equity-to-Asset is ranked higher than
91% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NEOG: 0.89 )
Ranked among companies with meaningful Equity-to-Asset only.
NEOG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.72  Med: 0.89 Max: 0.93
Current: 0.89
0.72
0.93
Interest Coverage No Debt
NEOG's Interest Coverage is ranked higher than
97% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.16 vs. NEOG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NEOG' s Interest Coverage Range Over the Past 10 Years
Min: 900.27  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 31.08
Beneish M-Score: -2.38
WACC vs ROIC
15.05%
13.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 17.14
NEOG's Operating Margin % is ranked higher than
86% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. NEOG: 17.14 )
Ranked among companies with meaningful Operating Margin % only.
NEOG' s Operating Margin % Range Over the Past 10 Years
Min: 15.68  Med: 17.96 Max: 20.75
Current: 17.14
15.68
20.75
Net Margin % 11.49
NEOG's Net Margin % is ranked higher than
85% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. NEOG: 11.49 )
Ranked among companies with meaningful Net Margin % only.
NEOG' s Net Margin % Range Over the Past 10 Years
Min: 10.59  Med: 11.83 Max: 13.23
Current: 11.49
10.59
13.23
ROE % 9.69
NEOG's ROE % is ranked higher than
68% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.95 vs. NEOG: 9.69 )
Ranked among companies with meaningful ROE % only.
NEOG' s ROE % Range Over the Past 10 Years
Min: 9.68  Med: 11.5 Max: 13.38
Current: 9.69
9.68
13.38
ROA % 8.65
NEOG's ROA % is ranked higher than
83% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.53 vs. NEOG: 8.65 )
Ranked among companies with meaningful ROA % only.
NEOG' s ROA % Range Over the Past 10 Years
Min: 8.65  Med: 9.79 Max: 11.42
Current: 8.65
8.65
11.42
ROC (Joel Greenblatt) % 36.56
NEOG's ROC (Joel Greenblatt) % is ranked higher than
74% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.23 vs. NEOG: 36.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NEOG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 33.35  Med: 38.98 Max: 52.57
Current: 36.56
33.35
52.57
3-Year Revenue Growth Rate 14.30
NEOG's 3-Year Revenue Growth Rate is ranked higher than
83% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. NEOG: 14.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NEOG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.3  Med: 14.5 Max: 26.4
Current: 14.3
5.3
26.4
3-Year EBITDA Growth Rate 11.30
NEOG's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. NEOG: 11.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NEOG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 2.6  Med: 16.3 Max: 42.9
Current: 11.3
2.6
42.9
3-Year EPS without NRI Growth Rate 9.00
NEOG's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. NEOG: 9.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NEOG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 5.6  Med: 15.5 Max: 27.7
Current: 9
5.6
27.7
GuruFocus has detected 6 Warning Signs with Neogen Corp $NEOG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NEOG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NEOG Guru Trades in Q1 2016

Chuck Royce 36,100 sh (New)
Jim Simons 154,300 sh (+23.34%)
Ron Baron 444,596 sh (unchged)
Mario Gabelli 16,500 sh (unchged)
» More
Q2 2016

NEOG Guru Trades in Q2 2016

Chuck Royce 41,350 sh (+14.54%)
Jim Simons 174,200 sh (+12.90%)
Ron Baron 444,596 sh (unchged)
Mario Gabelli 16,500 sh (unchged)
» More
Q3 2016

NEOG Guru Trades in Q3 2016

Mario Gabelli 16,900 sh (+2.42%)
Ron Baron 444,596 sh (unchged)
Chuck Royce 39,850 sh (-3.63%)
Jim Simons 161,000 sh (-7.58%)
» More
Q4 2016

NEOG Guru Trades in Q4 2016

Jim Simons 162,500 sh (+0.93%)
Ron Baron 444,596 sh (unchged)
Mario Gabelli 16,900 sh (unchged)
Chuck Royce 39,200 sh (-1.63%)
» More
» Details

Insider Trades

Latest Guru Trades with NEOG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325412    SIC: 2835
Compare:NAS:EXAS, NAS:PRXL, OTCPK:CZMWY, NYSE:ALR, NAS:PRAH, NAS:AXDX, NAS:MYGN, NAS:ABAX, NAS:ALOG, NAS:GHDX, NAS:BRKR, NYSE:CRL, NAS:FMI, NAS:BEAT, NYSE:ARA, NAS:QDEL, NAS:NEO, NAS:HSKA, NAS:VIVO, NAS:NRCIA » details
Traded in other countries:NG2.Germany,
Neogen Corp through its subsidiaries develops, manufactures and markets a line of products dedicated to food and animal safety.

Neogen Corp was formed as a Michigan corporation in June 1981 and actual operations began in 1982. The Company and subsidiaries develop, manufacture and market a diverse line of products dedicated to food and animal safety. The Company's food safety segment consists of diagnostic test kits and complementary products sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, drug residues, pesticide residues and general sanitation concerns. These products are marketed by company sales personnel in North America, the United Kingdom and other parts of Europe, Mexico and Brazil and by distributors through the rest of the world. The majority of the tests are disposable, single-use, immunoassay and DNA detection products that rely on the Company's proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. The Company's expanding line of food safety products also includes bioluminescence-based diagnostic technology. It operates in two primary business areas: the Food Safety segment, which develops and markets products for the detection of pathogens, natural toxins, allergens and other unwanted substances in food and feed products; and the Animal Safety segment, which develops and markets products and services dedicated to animal health. The products of food safety segment consist of diagnostic test kits and complementary products marketed to food and feed producers and processors to detect dangerous and/or unintended substances in food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, drug residues, pesticide residues and general sanitation concerns. Animal Safety's NeogenVet product line provides value-added products to the veterinary market. Top NeogenVet products include PanaKare, a digestive aid that serves as a replacement therapy where digestion of protein, carbohydrate and fat is inadequate due to exocrine pancreatic insufficiency; Natural Vitamin E-AD, which aids in the prevention and treatment of vitamin deficiencies in swine, cattle and sheep; and RenaKare, a supplement for potassium deficiency in cats and dogs. It manufactures its products in Lansing, Michigan; Lexington, Kentucky; Randolph, Wisconsin and Ayr, Scotland. The Company competes on the basis of ease of use, speed, accuracy and other similar performance characteristics of its products. It is subject to substantial governmental regulation.

Top Ranked Articles about Neogen Corp

Weekly CFO Buys Highlights Insiders invest in Neogen, Medical Transcription Billing, EVINE Live
According to GuruFocus' Insider Data, the recent CFO buys were: Neogen Corp. (NASDAQ:NEOG), Medical Transcription Billing Corp. (NASDAQ:MTBC) and EVINE Live Inc. (NASDAQ:EVLV). Read more...

Ratios

vs
industry
vs
history
PE Ratio 63.73
NEOG's PE Ratio is ranked lower than
89% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.58 vs. NEOG: 63.73 )
Ranked among companies with meaningful PE Ratio only.
NEOG' s PE Ratio Range Over the Past 10 Years
Min: 21  Med: 40.89 Max: 66.93
Current: 63.73
21
66.93
Forward PE Ratio 48.31
NEOG's Forward PE Ratio is ranked lower than
87% of the 45 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. NEOG: 48.31 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 63.73
NEOG's PE Ratio without NRI is ranked lower than
88% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.65 vs. NEOG: 63.73 )
Ranked among companies with meaningful PE Ratio without NRI only.
NEOG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 21  Med: 40.66 Max: 66.93
Current: 63.73
21
66.93
Price-to-Owner-Earnings 82.14
NEOG's Price-to-Owner-Earnings is ranked lower than
90% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.11 vs. NEOG: 82.14 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NEOG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 19.78  Med: 61.35 Max: 127.28
Current: 82.14
19.78
127.28
PB Ratio 5.75
NEOG's PB Ratio is ranked lower than
67% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. NEOG: 5.75 )
Ranked among companies with meaningful PB Ratio only.
NEOG' s PB Ratio Range Over the Past 10 Years
Min: 2.07  Med: 4.36 Max: 6.61
Current: 5.75
2.07
6.61
PS Ratio 7.34
NEOG's PS Ratio is ranked lower than
69% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. NEOG: 7.34 )
Ranked among companies with meaningful PS Ratio only.
NEOG' s PS Ratio Range Over the Past 10 Years
Min: 2.16  Med: 5.13 Max: 8.33
Current: 7.34
2.16
8.33
Price-to-Free-Cash-Flow 79.79
NEOG's Price-to-Free-Cash-Flow is ranked lower than
84% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.89 vs. NEOG: 79.79 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NEOG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 16.84  Med: 56.72 Max: 424.03
Current: 79.79
16.84
424.03
Price-to-Operating-Cash-Flow 56.88
NEOG's Price-to-Operating-Cash-Flow is ranked lower than
92% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.57 vs. NEOG: 56.88 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NEOG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.07  Med: 40.19 Max: 72.83
Current: 56.88
13.07
72.83
EV-to-EBIT 40.20
NEOG's EV-to-EBIT is ranked lower than
81% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.83 vs. NEOG: 40.20 )
Ranked among companies with meaningful EV-to-EBIT only.
NEOG' s EV-to-EBIT Range Over the Past 10 Years
Min: 13.2  Med: 25.35 Max: 43.4
Current: 40.2
13.2
43.4
EV-to-EBITDA 32.48
NEOG's EV-to-EBITDA is ranked lower than
84% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.07 vs. NEOG: 32.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
NEOG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.9  Med: 21.6 Max: 36.2
Current: 32.48
10.9
36.2
PEG Ratio 5.82
NEOG's PEG Ratio is ranked lower than
82% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. NEOG: 5.82 )
Ranked among companies with meaningful PEG Ratio only.
NEOG' s PEG Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.26 Max: 5.96
Current: 5.82
1.07
5.96
Shiller PE Ratio 94.02
NEOG's Shiller PE Ratio is ranked lower than
86% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.88 vs. NEOG: 94.02 )
Ranked among companies with meaningful Shiller PE Ratio only.
NEOG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 37.59  Med: 73.49 Max: 108.23
Current: 94.02
37.59
108.23
Current Ratio 8.52
NEOG's Current Ratio is ranked higher than
90% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. NEOG: 8.52 )
Ranked among companies with meaningful Current Ratio only.
NEOG' s Current Ratio Range Over the Past 10 Years
Min: 3.62  Med: 6.64 Max: 14.54
Current: 8.52
3.62
14.54
Quick Ratio 6.40
NEOG's Quick Ratio is ranked higher than
87% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. NEOG: 6.40 )
Ranked among companies with meaningful Quick Ratio only.
NEOG' s Quick Ratio Range Over the Past 10 Years
Min: 1.86  Med: 4.42 Max: 10.77
Current: 6.4
1.86
10.77
Days Inventory 134.94
NEOG's Days Inventory is ranked lower than
67% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.66 vs. NEOG: 134.94 )
Ranked among companies with meaningful Days Inventory only.
NEOG' s Days Inventory Range Over the Past 10 Years
Min: 125.82  Med: 136.29 Max: 182.11
Current: 134.94
125.82
182.11
Days Sales Outstanding 69.44
NEOG's Days Sales Outstanding is ranked lower than
54% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.91 vs. NEOG: 69.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
NEOG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.52  Med: 70.99 Max: 76.86
Current: 69.44
60.52
76.86
Days Payable 35.05
NEOG's Days Payable is ranked lower than
66% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.58 vs. NEOG: 35.05 )
Ranked among companies with meaningful Days Payable only.
NEOG' s Days Payable Range Over the Past 10 Years
Min: 24.07  Med: 37.73 Max: 48.27
Current: 35.05
24.07
48.27

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.40
NEOG's 3-Year Average Share Buyback Ratio is ranked higher than
69% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. NEOG: -1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NEOG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.9  Med: -2.2 Max: 2.1
Current: -1.4
-5.9
2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 27.83
NEOG's Price-to-Net-Cash is ranked lower than
77% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.06 vs. NEOG: 27.83 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NEOG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.89  Med: 29.74 Max: 194.8
Current: 27.83
3.89
194.8
Price-to-Net-Current-Asset-Value 10.57
NEOG's Price-to-Net-Current-Asset-Value is ranked lower than
61% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.95 vs. NEOG: 10.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NEOG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.95  Med: 7.63 Max: 17.26
Current: 10.57
1.95
17.26
Price-to-Tangible-Book 8.03
NEOG's Price-to-Tangible-Book is ranked lower than
69% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.33 vs. NEOG: 8.03 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NEOG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.58  Med: 5.14 Max: 9.8
Current: 8.03
1.58
9.8
Price-to-Intrinsic-Value-Projected-FCF 3.88
NEOG's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
69% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. NEOG: 3.88 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NEOG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.99  Med: 2.29 Max: 4.25
Current: 3.88
0.99
4.25
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.16
NEOG's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
75% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.71 vs. NEOG: 3.16 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.43
NEOG's Price-to-Median-PS-Value is ranked lower than
78% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. NEOG: 1.43 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NEOG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 0.6 Max: 1.63
Current: 1.43
0.26
1.63
Price-to-Peter-Lynch-Fair-Value 5.07
NEOG's Price-to-Peter-Lynch-Fair-Value is ranked lower than
90% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. NEOG: 5.07 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
NEOG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.44  Med: 1.87 Max: 5.72
Current: 5.07
0.44
5.72
Price-to-Graham-Number 4.77
NEOG's Price-to-Graham-Number is ranked lower than
68% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. NEOG: 4.77 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NEOG' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.91  Med: 2.69 Max: 5.4
Current: 4.77
0.91
5.4
Earnings Yield (Greenblatt) % 2.49
NEOG's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. NEOG: 2.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NEOG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.3  Med: 3.9 Max: 7.6
Current: 2.49
2.3
7.6
Forward Rate of Return (Yacktman) % 13.52
NEOG's Forward Rate of Return (Yacktman) % is ranked higher than
68% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. NEOG: 13.52 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NEOG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 10.5  Med: 17.9 Max: 21.6
Current: 13.52
10.5
21.6

More Statistics

Revenue (TTM) (Mil) $341.2
EPS (TTM) $ 1.03
Beta1.68
Short Percentage of Float3.23%
52-Week Range $43.79 - 69.09
Shares Outstanding (Mil)37.97

Analyst Estimate

May17 May18
Revenue (Mil $) 366 408
EPS ($) 1.15 1.36
EPS without NRI ($) 1.15 1.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NEOG

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlights Apr 05 2016 
Buffett-Munger Model Portfolio Outperforms Again - June Model Portfolio Performance Update Jun 05 2012 
Focusing on Predictable Companies, Value Strategies Continue to Outperform. Apr 02 2012 
The Most Overpaid and Underpaid CEOs Jan 19 2012 
Value Idea Contest Results Announcement Apr 12 2012 
Neogen: Food and Animal Safety Supplier Serves Long-Term Investors Well Oct 03 2011 
Neogen Corp. (NEOG) President & COO Lon M Bohannon sells 15,000 Shares Mar 04 2011 
Neogen Corp. (NEOG) President & COO Lon M Bohannon sells 5,000 Shares Mar 01 2011 
Neogen Corp. (NEOG) Chairman & CEO James L Herbert sells 11,641 Shares Feb 17 2011 
Neogen Corp. (NEOG) President & COO Lon M Bohannon sells 5,000 Shares Feb 01 2011 

More From Other Websites
Medtronic Poised on Strong Fundamentals Despite Several Woes Feb 24 2017
Omnicell: Q4 Report Disappoints, Aesynt Buyout Holds Promise Feb 24 2017
Align Expands Internationally with Dental Couture Buyout Feb 23 2017
Henry Schein Inks Agreement for Rijuven's CardioSleeve Feb 23 2017
Ecolab's (ECL) Earnings, Revenues Miss Estimates in Q4 Feb 21 2017
Medtronic (MDT) Beats on Q3 Earnings, Retains Sales View Feb 21 2017
Henry Schein to Acquire SAS to Strengthen Dental Offerings Feb 21 2017
Neogen Corp. breached its 50 day moving average in a Bullish Manner : NEOG-US : February 21, 2017 Feb 21 2017
GNC Holdings (GNC) Misses Q4 Earnings, Revenues Decline Y/Y Feb 17 2017
Medtronic's Freezor Xtra Catheter Gains FDA Nod for AVNRT Feb 17 2017
LabCorp (LH) Q4 Earnings and Revenues Beat, Offers View Feb 16 2017
Chemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View Feb 16 2017
Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss Feb 16 2017
Cynosure (CYNO) to be Acquired by Hologic in $1.65B Deal Feb 15 2017
Genomic Health (GHDX) Earnings Surpass Estimates in Q4 Feb 15 2017
Medtronic (MDT) Adds New Tools, Expands Coronary Suite Feb 14 2017
Bruker (BRKR) Beats on Q4 Earnings, Issues 2017 Guidance Feb 14 2017
Omnicell Partners with DCH Health for Sterile Compounding Feb 14 2017
Varian (VAR) Wins Competitive Bid for Six Shanghai Hospitals Feb 13 2017
STERIS (STE) Cuts 2017 View: Will it See Gloomy Days Ahead? Feb 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)